Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intensive glucose lowering has previously been shown to increase mortality among persons with advanced type 2 diabetes and a high risk of cardiovascular disease. This report describes the 5-year outcomes of a mean of 3.7 years of intensive glucose lowering on mortality and key cardiovascular events. METHODS: We randomly assigned participants with type 2 diabetes and cardiovascular disease or additional cardiovascular risk factors to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level of 7 to 7.9%). After termination of the intensive therapy, due to higher mortality in the intensive-therapy group, the target glycated hemoglobin level was 7 to 7.9% for all participants, who were followed until the planned end of the trial. RESULTS: Before the intensive therapy was terminated, the intensive-therapy group did not differ significantly from the standard-therapy group in the rate of the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) (P=0.13) but had more deaths from any cause (primarily cardiovascular) (hazard ratio, 1.21; 95% confidence interval [CI], 1.02 to 1.44) and fewer nonfatal myocardial infarctions (hazard ratio, 0.79; 95% CI, 0.66 to 0.95). These trends persisted during the entire follow-up period (hazard ratio for death, 1.19; 95% CI, 1.03 to 1.38; and hazard ratio for nonfatal myocardial infarction, 0.82; 95% CI, 0.70 to 0.96). After the intensive intervention was terminated, the median glycated hemoglobin level in the intensive-therapy group rose from 6.4% to 7.2%, and the use of glucose-lowering medications and rates of severe hypoglycemia and other adverse events were similar in the two groups. CONCLUSIONS: As compared with standard therapy, the use of intensive therapy for 3.7 years to target a glycated hemoglobin level below 6% reduced 5-year nonfatal myocardial infarctions but increased 5-year mortality. Such a strategy cannot be recommended for high-risk patients with advanced type 2 diabetes. (Funded by the National Heart, Lung and Blood Institute; ClinicalTrials.gov number, NCT00000620.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those levels predict the risk of cardiovascular disease.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Diabetic kidney disease might also play a role in the arrhythmia-associated mechanism of sudden death in this setting.655”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [655]
Experimental — accuracy not yet measuredIn the citing paper
“However, the belief that HbA1c was a surrogate marker was contradicted by findings from the ACCORD trial that diabetics randomly assigned to intensive treatment that reduced HbA1c levels in fact increased the risk of CVD events [14].”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“For example, intensive hypoglycemic treatments, such as oral hypoglycemics and insulin, substantially reduce fasting glucose and HbA1c levels.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“Similar U-shaped curves were found in a 7-year observational study of persons with T1D and a 22-year observational study of >20,000 persons with T2D.83,84”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citationEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Self-citationGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Huxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
Cited by
Items 101–200 of 1,000
García‐Ropero, Á., Badimón, J. J., & Santos‐Gallego, C. G. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1551877 · Cited by 161
“The glucose-lowering effects of SGLT2 inhibitors seem unlikely to explain these benefits since differences in HbA1c were (by design) minimal, improvement in glycemic control should translate into reduced incidence of MI/stroke (which were not different between arms), it takes years to show the benefits of glucose cont…”
BackgroundDeath during intensive glycemic therapy of diabetes: mechanisms and implications
Cryer, P. E. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.008 · Cited by 137
Luna-Marco, C., de Marañon, A. M., Hermo-Argibay, A., Rodriguez-Hernandez, Y., Hermenejildo, J., Fernandez-Reyes, M., Apostolova, N., Vila, J., Sola, E., Morillas, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102849 · Cited by 117
Comprehensive Cardiovascular Risk Factor Control Improves Survival
Bittner, V., Bertolet, M., Barraza Felix, R., Farkouh, M. E., Goldberg, S., Ramanathan, K. B., Redmon, J. B., Sperling, L., & Rutter, M. K. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.019 · Cited by 127
“Concerns were raised about the increased mortality associated with “aggressive” treatment of hyperglycemia among patients with T2DM in ACCORD (Action to Control Cardiovascular Risk in Diabetes Study) (9).”
BackgroundZhang, X., Zhu, Q., Chen, Y., Li, X., Chen, F., Huang, J., & Xu, B. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007165 · Cited by 127
“The beneficial effect on microvascular complications is well established for glycemic control, but the effect on macrovascular outcomes remains unclear.(3,4) In contrast, concern has been raised about the cardiovascular safety of antihyperglycemic drugs, since rosiglitazone was shown to increase risk of myocardial inf…”
Blackstone, R. P., Bunt, J. C., Cortés, M. C., & Sugerman, H. J. (2012) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2012.05.005 · Cited by 135
Hypoglycemia and Cardiovascular Risk: Is There a Major Link?
Hanefeld, M., Frier, B. M., & Pistrosch, F. (2016) · Diabetes Care · doi:10.2337/dcs15-3014 · Cited by 121
Vaes, A. W., Cheung, A., Atakhorrami, M., Groenen, M. T. J., Amft, O., Franssen, F. M. E., Wouters, E. F. M., & Spruit, M. A. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.810891 · Cited by 119
Foos, V., Varol, N., Curtis, B. H., Boye, K. S., Grant, D., Palmer, J. L., & McEwan, P. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1006730 · Cited by 120
The Treatment of Type 2 Diabetes
Pfeiffer, A. F. H., & Klein, H. H. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0069 · Cited by 209
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
“This finding is not surprising given the association between hypoglycaemia and adverse outcomes, such as hospitalization or ambulance attendance 73,74 , which is likely to be modifiable with the use of CGM to improve awareness of impending low blood levels of glucose 75 .”
Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus
White, W. B., Pratley, R., Fleck, P., Munsaka, M., Hisada, M., Wilson, C., & Menon, V. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12093 · Cited by 117
Garimella, P. S., Hart, P. D., O’Hare, A. M., DeLoach, S. S., Herzog, C. A., & Hirsch, A. T. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.02.340 · Cited by 124
Davis, T. M. E., Coleman, R. L., & Holman, R. R. (2013) · Circulation · doi:10.1161/circulationaha.112.000908 · Cited by 128
Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial
Sheng, C.-S., Tian, J., Miao, Y., Cheng, Y., Yang, Y., Reaven, P. D., Bloomgarden, Z. T., & Ning, G. (2020) · Diabetes Care · doi:10.2337/dc19-2589 · Cited by 109
Su, W., Chen, S., Huang, Y.-T., Huang, J., Wu, P.-Y., Hsu, W., & Lee, M. (2019) · Nutrients · doi:10.3390/nu11112838 · Cited by 121
“Second, cardiac autonomic neuropathy has been reported to potentially be a predisposing factor for CV events [39].”
BackgroundEdgar, L., Akbar, N., Braithwaite, A. T., Krausgruber, T., Gallart‐Ayala, H., Bailey, J. D., Corbin, A., Khoyratty, T. E., Chai, J. T., Alkhalil, M., et al. (2021) · Informationszentrum Lebenswissenschaften (ZB MED) · doi:10.1161/circulationaha.120.04646 · Cited by 113
Khunti, K., Damci, T., Meneghini, L., Pan, C. Y., Yale, J. ‐., & on behalf of the SOLVE Study Group (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01602.x · Cited by 114
“At the same time, the results of large trials designed to investigate the benefits of intensive glucose management on macrovascular endpoints have mostly proved negative [8].”
ResultGiorgino, F., Leonardini, A., & Laviola, L. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12044 · Cited by 118
Glucose targets for preventing diabetic kidney disease and its progression
Ruospo, M., Saglimbene, V. M., Palmer, S. C., De Cosmo, S., Pacilli, A., Lamacchia, O., Cignarelli, M., Fioretto, P., Vecchio, M., Craig, J. C., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010137.pub2 · Cited by 111
Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes
Hiyoshi, T., Fujiwara, M., & Zemin, Y. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160164 · Cited by 129
Cahill, L. E., Levy, A. P., Chiuve, S. E., Jensen, M. K., Wang, H., Shara, N. M., Blum, S., Howard, B. V., Pai, J. K., Mukamal, K. J., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.063 · Cited by 111
“Large randomized controlled trials of intensive glycemic control therapy among diabetic individuals have found significant reduction in cardiovascular outcomes in some (11), but not all (12,33), cohorts.”
BackgroundNovel metabolic biomarkers of cardiovascular disease
Jensen, M. K., Bertoia, M. L., Cahill, L. E., Agarwal, I., Rimm, E. B., & Mukamal, K. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.155 · Cited by 117
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Price, D. L., Chen, R., Udell, J., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.006 · Cited by 106
Cardiovascular Consequences of New-Onset Hyperglycemia After Kidney Transplantation
Wauters, R. P., Cosio, F. G., Suarez Fernandez, M. L., Kudva, Y., Shah, P., & Torres, V. E. (2012) · Transplantation · doi:10.1097/tp.0b013e3182584831 · Cited by 106
“Recent studies showed that tight control of glucose levels reduces the number of CV events in nontransplant patients with type 2 diabetes (13).”
BackgroundManagement of Cardiovascular Risk Factors in Adults With Congenital Heart Disease
Lui, G. K., Fernandes, S. M., & McElhinney, D. B. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001076 · Cited by 113
“Conclusion Adult patients with CHD are at an increased risk for acquired CVD.”
BackgroundInfluentialColom, C., Rull, A., Sánchez‐Quesada, J. L., & Pérez, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081798 · Cited by 119
“In fact, symptomatic and asymptomatic hypoglycemia are related to cardiac arrhythmias and increased mortality in T2DM patients [85,86].”
BackgroundHill, M. D. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00012-6 · Cited by 119
Copeptin is an independent predictor of diabetic heart disease and death
Enhörning, S., Hedblad, B., Nilsson, P. M., Engström, G., & Melander, O. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.11.020 · Cited by 109
Salvo, F., Moore, N., Arnaud, M., Robinson, P., Raschi, E., De Ponti, F., Bégaud, B., & Pariente, A. (2016) · BMJ · doi:10.1136/bmj.i2231 · Cited by 99
Terry, T., Raravikar, K., Chokrungvaranon, N., & Reaven, P. D. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0238-6 · Cited by 103
Classification and Diagnosis of Diabetes
GENUTH, S. M., Palmer, J. P., & Nathan, D. M. (2018) · Cited by 112
Blin, P., Lassalle, R., Dureau‐Pournin, C., Ambrosino, B., Bernard, M., Abouelfath, A., Gin, H., Jeunne, C. L., Pariente, A., Droz‐Perroteau, C., et al. (2012) · Diabetologia · doi:10.1007/s00125-011-2429-5 · Cited by 97
“In actual practice, human insulin might have been chosen for tighter control of diabetes [40–42], which has also been associated with higher mortality rates [43].”
BackgroundZhao, Y., Campbell, C. R., Fonseca, V., & Shi, L. (2012) · Diabetes Care · doi:10.2337/dc11-2048 · Cited by 94
Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions
Asghar, O., Alam, U., Hayat, S. A., Aghamohammadzadeh, R., Heagerty, A. M., & Malik, R. A. (2012) · Current Cardiology Reviews · doi:10.2174/157340312803760749 · Cited by 101
Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review
Hanefeld, M., Duetting, E., & Bramlage, P. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-135 · Cited by 93
“If T2D patients were treated with insulin, the overall rate of hypoglycaemia was reported to be low [11] and about one third that of patients with T1D [35]; however, when considering advanced stages of T2D, the frequency approaches that of T1D [7].”
BackgroundPrajapati, V. B., Blake, R., Acharya, L. D., & Seshadri, S. (2018) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902017000417144 · Cited by 92
“Education on self-control had more impact on controlling the condition and improving the quality of life as shown by one meta-analysis (Gerstein et al., 2011). According to the result of International Diabetes Federation (2015), there are 415 million people worldwide suffering from diabetes and 78.”
BackgroundMethodTreatment approach to type 2 diabetes: Past, present and future
Blaslov, K., Naranđa, F. S., Kruljac, I., & Renar, I. P. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i12.209 · Cited by 113
Au Yeung, S. L., Luo, S., & Schooling, C. M. (2018) · Diabetes Care · doi:10.2337/dc18-0289 · Cited by 92
“intensive glycemic control did not substantially reduce the risk of cardiovascular disease (CVD) events and may even have increased overall mortality (5), which remained evident after prolonged follow-up (6,7).”
Background(2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12770 · Cited by 92
Li, Q., Park, K., Li, C.-Z., Rask‐Madsen, C., Mima, A., Qi, W., Mizutani, K., Huang, P. L., & King, G. L. (2013) · Circulation Research · doi:10.1161/circresaha.113.301074 · Cited by 93
Diabetic cardiomyopathy and metabolic remodeling of the heart
Battiprolu, P. K., Lopez-Crisosto, C., Wang, Z. V., Nemchenko, A., Lavandero, S., & Hill, J. A. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.10.011 · Cited by 91
“however central to treatment, has not fulfilled hopes of meaningful morbidity and mortality benefit (Gerstein et al., 2011).”
BackgroundWhen financial incentives do more good than harm: a checklist
Glasziou, P., Buchan, H., Mar, C. D., Doust, J. A., Harris, M., Knight, R., Scott, A., Scott, I. A., & Stockwell, A. (2012) · BMJ · doi:10.1136/bmj.e5047 · Cited by 93
Yue, W., Lau, K. K., Siu, C., Wang, M., Yan, G.-H., Yiu, K., & Tse, H. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-113 · Cited by 92
“0% has been associated with increased all-cause mortality [27].”
BackgroundPromise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond
Martens, P., Mathieu, C., & Verbrugge, F. H. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0522-x · Cited by 99
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kirkman, M. S., Mahmud, H., & Korytkowski, M. T. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.002 · Cited by 95
Current management of diabetes mellitus and future directions in care
Chatterjee, S., & Davies, M. J. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-133200 · Cited by 85
Tandon, N., Ali, M. K., & Narayan, K. M. V. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11594650-000000000-00000 · Cited by 107
How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD
Hong, K. N., Fuster, V., Rosenson, R. S., Rosendorff, C., & Bhatt, D. L. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.001 · Cited by 80
O’Dell, J. R., Curtis, J. R., Mikuls, T. R., Cofield, S. S., Bridges, S. L., Ranganath, V. K., Moreland, L. W., & for the TEAR Trial Investigators (2013) · Arthritis & Rheumatism · doi:10.1002/art.38012 · Cited by 83
“As endocrinologists have taught us, tighter control is not always better (33).”
Wissing, K. M., & Pipeleers, L. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2013.12.004 · Cited by 89
“9% [107,108].”
Management of Type 2 Diabetes Mellitus in Older Adults
Kim, K., Kim, S. K., Sung, K. M., Cho, Y., & Park, S. W. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.5.336 · Cited by 99
“02) [29,30].”
Kutz, A., Kim, D. H., Wexler, D. J., Liu, J., Schneeweiß, S., Glynn, R. J., & Patorno, E. (2023) · Diabetes Care · doi:10.2337/dc23-0671 · Cited by 88
Update on Screening, Etiology, and Treatment of Dyslipidemia in Children
Bamba, V. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3860 · Cited by 94
“Therefore, prevention of dyslipidemia is partly related to glycemic control; long term studies have shown that improved glucose control is beneficial (50, 51).”
BackgroundRodríguez-Mañas, L., Bayer, A. J., Kelly, M., Zeyfang, A., Izquierdo, M., Laosa, O., Hardman, T. C., & Sinclair, A. J. (2014) · Trials · doi:10.1186/1745-6215-15-34 · Cited by 80
Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
Boyle, J. G., Livingstone, R., & Petrie, J. R. (2018) · Clinical Science · doi:10.1042/cs20171299 · Cited by 78
Roumie, C. L., Chipman, J., Min, J. Y., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Grijalva, C. G., Elasy, T., & Griffin, M. R. (2019) · JAMA · doi:10.1001/jama.2019.13206 · Cited by 76
Wang, C. C. L., & Reusch, J. E. B. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.036 · Cited by 82
Randomized Trials Versus Common Sense and Clinical Observation
Fanaroff, A. C., Califf, R. M., Harrington, R. A., Granger, C. B., McMurray, J. J. V., Patel, M. R., Bhatt, D. L., Windecker, S., Hernandez, A. F., Gibson, C. M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.069 · Cited by 80
Konieczyńska, M., Fil, K., Bazanek, M., & Undas, A. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-07-0566 · Cited by 80
HAT Brazil study group, Lamounier, R. N., Geloneze, B., Leite, S. O., Montenegro, R., Zajdenverg, L., Fernandes, M., de Oliveira Griciunas, F., Ermetice, M. N., & Chacra, A. R. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0379-5 · Cited by 72
Cardiovascular Disease in Diabetes Mellitus
Szuszkiewicz-Garcia, M., & Davidson, J. A. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.001 · Cited by 93
Brod, M., Wolden, M., Christensen, T., & Bushnell, D. M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12070 · Cited by 73
Age-related differences in glycaemic control in diabetes
Selvin, E., & Parrinello, C. M. (2013) · Diabetologia · doi:10.1007/s00125-013-3078-7 · Cited by 82
Management of diabetes mellitus in older people with comorbidities
Huang, E. S. (2016) · BMJ · doi:10.1136/bmj.i2200 · Cited by 79
Effect of Intensive Glycemic Control on Risk of Lower Extremity Amputation
Goldman, M. P., Clark, C. J., Craven, T. E., Davis, R. P., Williams, T. K., Velazquez-Ramirez, G., Hurie, J. B., & Edwards, M. S. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2018.09.021 · Cited by 70
Epigenetic Signatures and Vascular Risk in Type 2 Diabetes: A Clinical Perspective
Paneni, F., Costantino, S., Volpe, M., Lüscher, T. F., & Cosentino, F. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.003 · Cited by 70
2013 ESH/ESC Guidelines for the management of arterial hypertension
(2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.07.015 · Cited by 75
Vedin, O., Hagström, E., Stewart, R., Brown, R. G., Krug‐Gourley, S., Davies, R., Wallentin, L. C., White, H. D., & Held, C. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312444995 · Cited by 82
Treatments for diabetic neuropathy
Bril, V. (2012) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2012.00391.x · Cited by 78
Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic
King, R., & Grant, P. J. (2016) · Herz · doi:10.1007/s00059-016-4414-8 · Cited by 82
“Given the similar HbA1c in the intensive arms of both trials, it has been postulated that an increased frequency of hypoglycaemia in the ACCORD study might account for these differences, but this has yet to be proven conclusively [73].”
BackgroundHemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub2 · Cited by 69
RetractedEgger, A., Niederseer, D., Diem, G., Finkenzeller, T., Ledl-Kurkowski, E., Forstner, R., Pirich, C., Patsch, W., Weitgasser, R., & Niebauer, J. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450132 · Cited by 67
Variability in hemoglobin A1c predicts all-cause mortality in patients with type 2 diabetes
Ma, W.-Y., Li, H., Pei, D., Hsia, T., Lu, K., Tsai, L., Wei, J., & Su, C. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.03.028 · Cited by 70
“However, recent large clinical trials failed to lower all-cause mortality by lowering glucose to near-normal levels (Gerstein et al., 2008; Patel et al., 2008; Duckworth et al., 2009; Gerstein et al., 2011).”
BackgroundMetabolic Syndrome and Cardiometabolic Risk Factors
Papakonstantinou, E., Lambadiari, V., Dimitriadis, G., & Zampelas, A. (2014) · Current Vascular Pharmacology · doi:10.2174/15701611113116660176 · Cited by 68
ORIGIN Trial Investigators (2016) · Diabetes Care · doi:10.2337/dc15-1676 · Cited by 66
Renal physiology of glucose handling and therapeutic implications
Cherney, D. Z. I., Kanbay, M., & Lovshin, J. A. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz230 · Cited by 73
Standl, E., Stevens, S. R., Lokhnygina, Y., Bethel, M. A., Buse, J. B., Gustavson, S. M., Maggioni, A. P., Mentz, R. J., Hernandez, A. F., & Holman, R. R. (2020) · Diabetes Care · doi:10.2337/dc19-1079 · Cited by 65
Moreno, G., & Mangione, C. M. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12513 · Cited by 65
“In the ACCORD-BP trial, hypoglycemia was more common in older adults, and greater mortality was found in the intensive glucose control group than in the lessintensive usual care group.(36,37) The RCTs reviewed do not provide supportive evidence that intensive glycemic control (HbA1c <6% or <6.”
Backgroundon behalf of the ESCARVAL STUDY GROUP, Navarro-Pérez, J., Orozco‐Beltrán, D., Gil-Guillén, V. F., Pallarés‐Carratalá, V., Valls, F., Fernández, A. G., Perez-Navarro, A. M., Sanchís, C., Dominguez-Lucas, A., et al. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0914-1 · Cited by 72
“Action to Control Cardiovascular Risk in Diabetes (ACCORD) [9]; the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) [10], and the Veterans Affairs Diabetes Trial (VADT) [11], suggested different effects of glycemic control in patients with and without pr…”
BackgroundCardiovascular Disease in Diabetes: Where Does Glucose Fit In?
Reusch, J. E. B., & Wang, C. C. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-3011 · Cited by 68
Chen, J., Yin, D., & Dou, K. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01875-8 · Cited by 84
“2 years of standard glycemic therapy [36, 37].”
DPP-4 inhibitors: focus on safety
Tella, S. H., & Rendell, M. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.977863 · Cited by 63
“5-fold increase in hypoglycemic events [135].”
Metabolism of the failing heart and the impact of SGLT2 inhibitors
García‐Ropero, Á., Santos‐Gallego, C. G., Zafar, M. U., & Badimón, J. J. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1588886 · Cited by 67
“to be explained by a tight glycemic control, since it takes years to observe this effect and even then, it is still controversial whether this improved glycemic control may reduce mortality or HF [45].”
BackgroundUncovering undetected hypoglycemic events
Unger, J. (2012) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s29367 · Cited by 62
Association of Glycation Gap With Mortality and Vascular Complications in Diabetes
Nayak, A., Nevill, A. M., Bassett, P., & Singh, B. M. (2013) · Diabetes Care · doi:10.2337/dc12-1040 · Cited by 68
“0% (42 mmol/mol) stands out as having led to increased mortality with tighter glycemic targets for uncertain reasons (35).”
Houston, M. C. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944717743920 · Cited by 70
Berenson, D. F., Weiss, A. R., Wan, Z., & Weiss, M. A. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06468.x · Cited by 60
Australian Nurse Practitioner Practice: Value Adding through Clinical Reflexivity
Woods, M., & Murfet, G. O. (2015) · Nursing Research and Practice · doi:10.1155/2015/829593 · Cited by 61
Gao, S., Liu, Q., Ding, X., Chen, H., Zhao, X.-Q., & Li, H. (2019) · Angiology · doi:10.1177/0003319719875632 · Cited by 62
Pei, J., Wang, X., Pei, Z., & Hu, X. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02026-9 · Cited by 72
Bloomfield, H. E., Greer, N. L., Newman, D. R., MacDonald, R. H., Carlyle, M. H., FITZGERALD, P. J., Rutks, I. R., & Wilt, T. J. (2012) · PubMed · Cited by 89
Lundqvist, A., Steen Carlsson, K., Johansen, P., Andersson, E., & Willis, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110235 · Cited by 59
The Israel Diabetes and Cognitive Decline (IDCD) study: Design and baseline characteristics
Beeri, M. S., Ravona‐Springer, R., Moshier, E. L., Schmeidler, J., Godbold, J., Karpati, T., LeRoith, D., Koifman, K., Kravitz, E., Price, R., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.06.002 · Cited by 60
“Combined with the nonsignificant effects on other ACCORD outcomes, and increased mortality in participants in the intensive treatment group [44], the ACCORD findings do not support”
ResultShah, H. S., Gao, H., Morieri, M. L., Skupien, J., Marvel, S., Paré, G., Mannino, G. C., Buranasupkajorn, P., Mendonca, C., Hastings, T., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0285 · Cited by 60
Crutzen, S., Baas, G., Abou, J., van den Born-Bondt, T., Hugtenburg, J. G., Bouvy, M. L., Heringa, M., Taxis, K., & Denig, P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01268 · Cited by 63
“Whether in older patients intensive glycemic and blood pressure control is more beneficial than harmful has been a matter of debate (Bejan-Angoulvant et al., 2010; Cushman et al., 2010; Gerstein et al., 2011; Sue Kirkman et al., 2012; Vijan et al., 2014; Beddhu et al., 2018;Williamson et al., 2019).”
BackgroundThe Role of Biofactors in Diabetic Microvascular Complications
Ziegler, D., Porta, M., Παπάνας, Ν., Moța, M., Jermendy, G., Beltramo, E., Mazzeo, A., Caccioppo, A., Striglia, E., Serhiyenko, V. A., et al. (2021) · Current Diabetes Reviews · doi:10.2174/1871527320666210825112240 · Cited by 61
Zhao, N., Yu, X., Zhu, X., Song, Y., Gao, F., Yu, B., & Qu, A. (2023) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-023-10470-x · Cited by 68
“However, in T2DM, lowering glucose had no or moderate effect on atheroscle-rosis-related vascular outcomes [137, 138].”
Brod, M., Wolden, M., Christensen, T., & Bushnell, D. M. (2013) · Value in Health · doi:10.1016/j.jval.2013.09.002 · Cited by 56
“[4] Gerstein HC, Miller ME, Genuth S, et al.”
Background
Metadata
- Authors
- The ACCORD Study Group
- Affiliations
- McMaster University (CA)
- Corresponding author
- The ACCORD Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-03
- Volume
- 364
- Issue
- 9
- Pages
- 818-828
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4083508
- OpenAlex
- W2125468958
- Cited by
- 1,035
- References
- 18
- Citations by year
- 2026: 12 · 2025: 33 · 2024: 27 · 2023: 35 · 2022: 29 · 2021: 61 · 2020: 51 · 2019: 53 · 2018: 81 · 2017: 78 · 2016: 80 · 2015: 91 · 2014: 100 · 2013: 108 · 2012: 120
- FWCI
- 104.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, Y1-HC-9035, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, N01 HC095180, Y01 HC009035, Y1-HC-1010, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, HbA1c, cardiovascular outcomes, mortality, myocardial infarction, stroke, cardiovascular disease, glycemic targets, hypoglycemia, adverse events, long-term follow-up, EXSCEL trial
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Proportional Hazards Models, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.